If FCR is definitely the therapy of option, warning need to be taken in sufferers with NOTCH1 mutations, in whom rituximab appears to own tiny included benefit.59 Other genomic subgroups, which include patients with BIRC3 mutations surface to derive minor benefit from CIT,111,112 but these effects needs to be even further validated.Usia nominal unt